1. Home
  2. VRDN vs ROOT Comparison

VRDN vs ROOT Comparison

Compare VRDN & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRDN
  • ROOT
  • Stock Information
  • Founded
  • VRDN 2006
  • ROOT 2015
  • Country
  • VRDN United States
  • ROOT United States
  • Employees
  • VRDN N/A
  • ROOT N/A
  • Industry
  • VRDN Medical Specialities
  • ROOT Property-Casualty Insurers
  • Sector
  • VRDN Health Care
  • ROOT Finance
  • Exchange
  • VRDN Nasdaq
  • ROOT Nasdaq
  • Market Cap
  • VRDN 1.6B
  • ROOT 1.7B
  • IPO Year
  • VRDN N/A
  • ROOT 2020
  • Fundamental
  • Price
  • VRDN $13.13
  • ROOT $129.74
  • Analyst Decision
  • VRDN Buy
  • ROOT Buy
  • Analyst Count
  • VRDN 12
  • ROOT 7
  • Target Price
  • VRDN $36.44
  • ROOT $101.33
  • AVG Volume (30 Days)
  • VRDN 1.2M
  • ROOT 727.2K
  • Earning Date
  • VRDN 05-07-2025
  • ROOT 05-07-2025
  • Dividend Yield
  • VRDN N/A
  • ROOT N/A
  • EPS Growth
  • VRDN N/A
  • ROOT N/A
  • EPS
  • VRDN N/A
  • ROOT 1.83
  • Revenue
  • VRDN $302,000.00
  • ROOT $1,176,500,000.00
  • Revenue This Year
  • VRDN N/A
  • ROOT $12.28
  • Revenue Next Year
  • VRDN $20,553.29
  • ROOT $12.34
  • P/E Ratio
  • VRDN N/A
  • ROOT $70.90
  • Revenue Growth
  • VRDN N/A
  • ROOT 158.57
  • 52 Week Low
  • VRDN $9.90
  • ROOT $34.04
  • 52 Week High
  • VRDN $27.20
  • ROOT $181.14
  • Technical
  • Relative Strength Index (RSI)
  • VRDN 46.75
  • ROOT 50.54
  • Support Level
  • VRDN $9.90
  • ROOT $113.59
  • Resistance Level
  • VRDN $14.22
  • ROOT $134.53
  • Average True Range (ATR)
  • VRDN 1.17
  • ROOT 11.77
  • MACD
  • VRDN 0.18
  • ROOT -0.40
  • Stochastic Oscillator
  • VRDN 74.77
  • ROOT 76.50

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

About ROOT Root Inc.

Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.

Share on Social Networks: